Infection Prevention Central Venous Catheter

The Bactiguard Infection Protection Central Venous Catheter, BIP CVC, with Bactiguard coating, reduces the risk of microbial adhesion and colonization. Bactiguard coated CVCs have been shown to reduce catheter-related infections in high-risk patients, when compared to uncoated CVC.The Bactiguard Infection Protection (BIP) technology is based on the application of a very thin noble metal coating, consisting of gold, palladium and silver, to medical devices. The Bactiguard coating is firmly bound to the surface of the device and reduces the adhesion and growth of microbes.

The BIP CVC is used to administer drugs and intravenous solutions and to sample blood. It is made of polyurethane, coated with Bactiguard coating, and can be used up to 30 days.

Catheter related bloodstream infections (CBRSI)

Catheter related bloodstream infections (CBRSI), also known as Central Line Associated Bloodstream Infections (CLABSI), account for a large proportion of healthcare associated infections (HAI) in patients using medical devices, such as central venous catheters (CVC)1. These infections can lead to serious complications, causing patient suffering as well as increased mortality and healthcare costs. In addition, many of these infections are treated with antibiotics, which increase the risk of emergence and spread of multi-resistant microbes. WHO estimates that antimicrobial resistance is so serious that it threatens the achievements of modern medicine2.

Contact me, I want to know more

I want to order and I am interested in knowing more about Bactiguard’s products

CLINICALLY PROVEN EFFECTIVE AGAINST INFECTIONS

In a clinical study of Bactiguard coated central venous catheters it was concluded that the coating significantly reduced the incidence of infections by 52%. The investigation included 233 hematological oncology patients, 113 received standard uncoated catheters and 120 received Bactiguard coated catheters. Catheter related infection developed in 21% of patients with the standard catheter but only in 10% of the patients with the Bactiguard coated catheters3. The Bactiguard coating has a proven strong biocompatibility profile in blood. A further analysis of data proved no increased risk for adverse events such as thrombosis and hemolysis, when using the Bactiguard coated product4.

Tissue-friendly and safe technology

The Bactiguard solution is unique, tissue friendly and safe for patient use. As opposed to other coating technologies, which depend on the release of substances, that kill bacteria, e.g. large amounts of silver ions, chlorhexidine or antibiotics, the Bactiguard coating is neither toxic nor pharmacologic5. To date, more than 180 million Bactiguard coated urinary catheters have been sold for patient use, with no reported adverse events related to the coating.

References
1. Klevens RM et al, Public Health Rep. 2007 Mar-Apr;1222):160-6
2. Kalra OP et al, J Glob Infect Dis. 2009 Jan;1(1):57-63
3. Goldschmidt H.et al., Zbl. Bakt.1995; 233: 215-223
4. Harter et al, Cancer. 94 (1):245-251 (2002)
5. Data on file